Payment overview · 2025
General Payments
$139.21
7 reported records · 4 companies
Healthcare provider profile · identity verified
Mahrukh Khan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · ST. LOUIS, MO · NPI 1568596336
Verified facts
What the public records show
CMS Open Payments records show Mahrukh Khan, M.D. received $139.21 in general payments during 2025 across 7 reported records.
Lilly USA, LLC accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71.62 | 51.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.04 | 17.3% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $23.18 | 16.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.37 | 14.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $139.21 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $71.62 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.94 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 134 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
134 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
191 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 576 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 459 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 423 | 106 |
| Lisinopril | Lisinopril | 330 | 79 |
| Metformin Hcl | Metformin Hcl | 314 | 73 |
| Montelukast Sodium | Montelukast Sodium | 294 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 285 | 61 |
| Omeprazole | Omeprazole | 257 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 237 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 52 |
| Furosemide | Furosemide | 214 | 71 |
| Losartan Potassium | Losartan Potassium | 199 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 47 |
| Carvedilol | Carvedilol | 194 | 34 |
| Ozempic | Semaglutide | 191 | 37 |
| Gabapentin | Gabapentin | 182 | 43 |
| Famotidine | Famotidine | 178 | 37 |
| Azithromycin | Azithromycin | 177 | 135 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 162 | 42 |
| Lovastatin | Lovastatin | 148 | 37 |
| Eliquis | Apixaban | 147 | 23 |
| Simvastatin | Simvastatin | 146 | 37 |
| Potassium Chloride | Potassium Chloride | 138 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 30 |
| Mounjaro | Tirzepatide | 134 | 25 |
| Allopurinol | Allopurinol | 130 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 29 |
| Trazodone Hcl | Trazodone Hcl | 121 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 29 |
| Spironolactone | Spironolactone | 110 | 24 |
| Ezetimibe | Ezetimibe | 107 | 21 |
| Atenolol | Atenolol | 94 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 36 |
| Mirtazapine | Mirtazapine | 86 | 14 |
| Alprazolam | Alprazolam | 80 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 11 |
| Prednisone | Prednisone | 72 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 25 |
| Jardiance | Empagliflozin | 61 | 16 |
| Lidocaine | Lidocaine | 60 | 14 |
| Donepezil Hcl | Donepezil Hcl | 57 | 14 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Finasteride | Finasteride | 51 | suppressed |
| Torsemide | Torsemide | 50 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 13 |
| Trulicity | Dulaglutide | 46 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Linzess | Linaclotide | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 41 | 41 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 15 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 16 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 26 |
| Cephalexin | Cephalexin | 38 | 18 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 25 |
| Rivastigmine | Rivastigmine Tartrate | 35 | 11 |
| Levofloxacin | Levofloxacin | 34 | 27 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 18 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 15 |
| Promethazine Hcl | Promethazine Hcl | 27 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 15 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 21 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 12 |
| Irbesartan | Irbesartan | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $139.21 · 7 records | Lilly USA, LLC | MOUNJARO, Omnipod, QULIPTA, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error